Hyperkalemia: Prevalence, Predictors and Emerging Treatments-Reference-Cited by-同舟云学术

Hyperkalemia: Prevalence, Predictors and Emerging Treatments

Published:2022-12-12 Issue:1 Volume:12 Page:35-63
ISSN:2193-8261
Container-title:Cardiology and Therapy
language:en
Short-container-title:Cardiol Ther

Author:

Larivée Natasha L.,Michaud Jacob B.,More Keigan M.,Wilson Jo-Anne,Tennankore Karthik K.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40119-022-00289-z.pdf

Reference141 articles.

1. Kanda E, Kashihara N, Kohsaka S, Okami S, Yajima T. Clinical and economic burden of hyperkalemia: a nationwide hospital-based cohort study in Japan. Kidney Med Nov-Dec. 2020;2(6):742-752.e1. https://doi.org/10.1016/j.xkme.2020.09.003.

2. Hougen I, Leon SJ, Whitlock R, et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int Rep. 2021;6(5):1309–16. https://doi.org/10.1016/j.ekir.2021.02.038.

3. Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202–10.

4. Kovesdy CP, Matsushita K, Sang Y, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535–42. https://doi.org/10.1093/eurheartj/ehy100.

5. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–21. https://doi.org/10.1159/000479802.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coste-efectividad del ciclosilicato de sodio y zirconio para el tratamiento de la hiperpotasemia en pacientes con enfermedad renal crónica o insuficiencia cardiaca en España;Nefrología;2024-09

2. Finerenone: Who Should Prescribe It for Chronic Kidney Disease? Nurse Practitioner Perspectives;The Journal for Nurse Practitioners;2024-07

3. Anti-hepatopathy and anti-nephropathy activities of Taraxacum officinale in a rat model of Streptozotocin diabetes-induced hepatorenal toxicity and dyslipidemia via attenuation of oxidative stress, inflammation, apoptosis, electrolyte imbalances, and mitochondrial dysfunction;Aspects of Molecular Medicine;2024-06

4. Optimizing Finerenone in People With Diabetes and Chronic Kidney Disease: An Opportunity for the Pharmacist;Journal of Pharmacy Practice;2024-05-28

5. Evaluation of Insulin Dosing Strategies for Hyperkalemia Management at an Academic Medical Center;Clinical Therapeutics;2024-05